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Abstract
While herbal medicines hold great promises for treating diseases, they also have serious lim-
itation in their current forms. Currently the regulatory scheme for herbal medicines in the
United States is inadequate and it undercuts the incentives for American industry to develop
drug products from herbal medicines. This paper argues that FDA should develop a drug
model for herbal medicines. This will help both to mainstream herbal medicines in the United
States, and to alleviate the production crisis that the American pharmaceutical industry is
facing. This paper also assesses FDA's new Draft Guidance for Botanical Drug Products for
its incentivizing eects on the industry.
Introduction
In the past few years, herbal medicines have attracted strong attention in the United States and
worldwide, as part of a larger fascination with natural products. This paper explores the future of
herbal medicines in the United States and seeks to make the case that botanical drugs, as a new
drug model for herbal medicines, will lend much-needed arsenal in the perennial ght against human
diseases.
The current regulatory state of aair regarding herbal medicines is sub-optimal as it fails to spur
rigorous research and development eorts into herbal medicines. Due to the unfavorable regulatory
climate, few US companies are engaged in developing drug products from herbal medicines. FDA
ought to promote industry eorts in exploring herbal medicines by approving botanical drugs with
substantially lower standard. Such policy will benet both consumers and the pharmaceutical industry
suering a \dry spell" in conventional drug development.
1The rst section of this paper illustrates the huge market potential for herbal medicines within
the United States and globally. It points out that this market potential could be curtailed by lack of
standardization and scientic validation for many herbal medicines. The second section examines the
crisis the American pharmaceutical industry is facing and the limitation of the conventional \silver
bullet" approach in drug development. The third section contends that developing botanical drugs
from herbal medicines can bring the better of the two worlds together. It promises to alleviate the \dry
spell" the pharmaceutical industry is facing, and bring more eective medicines to patients at faster
rate. The fourth section examines the current regulatory climate and points to the disincentive eect
of the current regulations. Rationales for adopting a lower standard for botanical drug approval are
discussed. The last section assesses The Draft Guidance for the Industry: Botanical Drug Products
(Hereinafter \Draft Guidance"), released by FDA in August 2000, for its incentives on industry eorts
in the eld of developing drug models for herbal medicines. Finally, this paper proposes further changes
to be adopted in the nal Guidance.
2I.
The Market: US and Worldwide
The projected market size for herbal medicine in the market worldwide is staggering. One study
estimates the global market at about 18 to 20 billion US dollars in 1997.2 Among these, Asia dominates
as the largest market at about 40% share, Europe follows at 35%, and North America accounts for
about 17%.3
The America market is equally promising. Partially fueled by the passage of the Dietary Supplement
Health and Education Act (DSHEA), the US market has seen a rise in the sales of herbal products
in the form of dietary supplements from 3.3 billion to 6.5 billion between 1990 and 1996.4 The rise in
the sale of these products can be directly attributed to the increase of people using herbs. Within a
short span of seven years from 1991 to 1998, the percentage of the American population using herbs
increased from a bare 4% to a signicant 30-35% in 1998.5
In spite of the staggering growth, the US market still has plenty of room to grow. As America is late
to catch the trend of consuming herbal products, other nations' consumption patterns may shed light
on the direction of the US market. For instance, over 60% of the population in Germany, and 80-90%
of the population in China and uses herbs regularly.6 By inference, the US market is still capable of
expanding to reach another 30 or 40% of the population, making US an enticing market given the
consumption power of the US consumers.
3The simple logical inference, however, may not stand. Many factors, including cultural, traditional
and infrastructural ones, contribute to consumers' purchase choices in medicines. Take China as
example, using plant-derived remedies to treat diseases is part of its national cultural heritage. The
practice of traditional Chinese medicine dates back to as early as 2800 B.C., as documented in the
\Herbal Classic of the Divine Plowman" (Sheng Nung Ben Cao Chien).7 As an indication of the
prevalence of traditional Chinese medicine (TCM), China now boasts more than 2500 TCM hospitals,
30 universities and colleges engaging in the studies of TCM.8 Chinese government, consumers and
medical professionals hold TCM and western medical science at equal status. Given the tradition and
the supportive infrastructures in place, it comes as no surprise that 80-90% of the Chines population
use herbs on a regular basis.
4US, on the other hand, is a study in stark contrast. The faith in FDA-approved prescription drug
and OTC drugs is deeply ingrained in US consumers. On the one hand, the medical profession, con-
servative by training, is understandably reluctant to embrace herbal medicine. On the other hand, the
practice of herbal medicine such as traditional Chinese medicine, remains largely conned to China
towns in large coastal cities in the US. As a result, while many consumers recognize the merits of herbal
medicine, the American mainstream remains ambivalent about the ecacy of herbal medicines. Such
ambivalence makes further expansion of the herbal medicine market in US a questionable prospect.
The growth trend of the US dietary supplement market to date seems to vindicate this concern. After
the astonishing growth from 1994 to 1997, the US market for dietary supplements has leveled o in
1998, and there may even be a lessening in demand.9 The shift in trend is fueled partly by a hostile
press hot on the pursuit of fraudulent manufacturers, partly by the long-held western perception that
these herbal medicines are in the league of quackery. This plateau in sales growth highlights the
concern about the sustainability of herbal medicines in their traditional form in the US market.
While the attening growth leaves the future of the dietary supplement industry uncertain, it presents
an unique opportunity for American pharmaceutical companies, who so far have largely stayed o the
market of herbal medicine supplies. The opportunity lies in developing botanical drugs, an approach
that combines the merits of advanced western technology with the empirical-based century-old herbal
medicine knowledge.
A clarication of terminology is due here. A botanical drug, as dened by FDA in its Draft Guid-
ance, is a botanical product that is prepared from a botanical drug substance, and is intended for use
as a drug. A conventional FDA-approved drug has a single well-characterized active ingredient. In
contrast, a botanical drug, by denition, comes in forms of extracts that are composed of multiple
chemical constituents.
The development of botanical drugs, given the right regulatory climate, will allow American pharma-
ceutical companies to capitalize on the existing market for herbal medicines, both US and worldwide,
and to expand and reach those consumers traditionally suspicious of herbal medicines.
5II.
Crisis in Conventional Drug Discovery
The American pharmaceutical industry is currently in the midst of a productivity crisis. To better
understand the plight of pharmaceutical companies, it is necessary to briey recap the drug approval
process for a new chemical entity (NCE) drug.
Conventional FDA Drug Approval Process
Before starting human clinical trials in the United States, a company must le an investigational
new drug (IND) application with the FDA. FDA has 30 days to intervene. If FDA fails to inter-
vene within the 30 days, the company may proceed with testing. The tests are divided into three
phases. In the Phase I clinical trial, companies test for safety on twenty to eighty healthy volunteers.
Before administrating the drug to volunteers, companies need to supply preclinical data, including
pharmacological and toxicological data, which are subject to the review by clinical pharmacologists.
If the data are deemed satisfactory, the drug is then administrated to the volunteers. In the Phase
II, companies test for ecacy of the drug in 100-300 patients under dierent dosages. The Phase III
calls for extensive trials on hundreds or even thousands of patients. Usually at least two adequate
and well-controlled Phase III studies are required. The objective is to establish proof of ecacy and
acceptable side eects. If the drug remains promising after all three phases, then the company submits
to FDA clinical, pharmacological and toxicological data in the form of a new drug application (NDA).
Currently, it takes FDA on average 2 to 3 years to evaluate and approve a NDA.10
Drying Drug Pipelines
6The American pharmaceutical industry is in the midst of a productivity crisis. Jean-Pierre Gar-
nier, the chief executive of GlaxoSmithKline recently lamented that \We don't have enough in our
collective pipelines".11 Apparently, this is not a problem limited to the isolated few, but one that
plagued the pharmaceutical industry across the board. In 2000, the Wall Street Journal reported that
since 1996, the production of breakthrough drugs has steadily declined.12 In 1996, there were 53 new
FDA-approved drugs. The number went down to 35 in 1999, and 16 through the rst half of 2000.13
Kenneth Kaitin, director of the Tufts Center for the Study of Drug Development, summed it up:
\...these [pharmaceutical] rms will need to put out at least three or four new chemical entities per
year [to sustain growth rates] and there's no rm right now doing anything more than one per year.
It is a very tenuous time for the pharmaceutical industry."14
More recent news conrmed that the trouble continues for large pharmaceutical companies. Merck,
Bristol-Myers Squibb, Schering-Plough and Eli Lily have all recently issued warnings on their prospec-
tive earnings.15 Patent expiration of their major drugs, combined with the lack of new drugs led to
the earning woes.16 As patents continue to expire and no new drugs on the horizon, the prospect of
a recovery in productivity is slim.
Worse than the decline in productivity is how these pharmaceutical companies responded. Rather
than beeng up research, a Wall Street Journal article reported, \the pharmaceutical industry is
gradually shifting the core of its businesses away from the unpredictable and increasingly expensive
task of creating drugs and toward the steadier business of marketing them."17 While this strategy is
working in the short term to boost the bottom line, it will not solve the productivity problem in the
long run. Ultimately, patients will suer, and the society at large will pay through increased medical
expenses for patient care.
7The costly FDA approval process adds further salt to the injury. Bringing a single new chemical
entity (NCE) drug to market now takes 10-15 years on average, and costs over 800 million dollars,
exceeding the gross national product of some nations.18 Moreover, this cost is steadily rising at the
rate of 6% annually.
A signicant portion of the cost comes from candidate attrition during the clinical stage of the
FDA approval process.19 For every ve to six drug candidates that reach Investigational New Drug
(IND) status, only one lucky star survives to become a product.20 To illustrate the point from a
dierent angle, pharmaceutical companies will typically market only roughly one out of a hundred
of their patented products.21 The skyrocketing costs of the R&D costs have translated directly into
soaring price tags for prescription drugs. As a Wall Street Journal article observed, drugs \commonly
[cost] no more than $2 a pill a few years ago. The new-generation drugs cost $4, $11, even $15 per
pill". 22
Lost faith in \Silver Bullets"
8The current crisis in new drug discovery highlights the limitation of conventional \silver bullet"
view of drugs. The traditional belief in \silver bullets", a single drug that takes care of a single
disease, rests on a critical premise that human diseases have a uniform underlying genetic basis across
patients populations. Typically, a \silver bullet" drug is a new chemical entity (NCE) drug with a
single active chemical ingredient. While there have been blockbuster \silver bullets" like Amgen's
EPO and Eli Lily's Prozac, the hope in new blockbuster drugs has been waning. Recent advances
in genomics vindicate this pessimism. It now appears that diverse genetic changes often underline a
single disease, a phenomenon termed \polymorphism". Thus dierent patient populations may require
dierent drugs tailored to their needs. The polymorphic nature of diseases suggests an individualized
approach in drug design is more likely to succeed.23
In sum, the American pharmaceutical industry is in a \terrible trough".24 There is a dire need
to nd a complementary way to supplant their current approach toward drug discovery. Some pin
their hopes on the advent of genomics and the complete sequences of human genome. While genomic
knowledge will undoubtedly oer new insights into the human diseases, most experts in genomics
think that signicant drug discoveries based on genomics are still years away.25 Given the heightened
interest in herbal medicines in the United States and worldwide, developing botanical drugs based on
herbal medicines may be the booster shot that the industry badly needs.
III.
Botanical Drugs: A Marriage Between Herbal Medicines and Western Drug
Development
What Herbal Medicines Oer
9Herbal medicines oer hope to alleviate the current crisis in the conventional drug development.
It is important to stress here that herbal medicines will not be \alternative", in the sense that it
will replace conventional drugs. But rather, they will be \complementary" to the conventional drug
discovery. At least three reasons explain why herbal medicines may oer the perfect complement to
the ailing conventional drug discovery.
First, capitalizing on herbal medicine knowledge may give rise to a cheaper and faster way to
drug discovery. Typically, drug discovery starts with screening millions of chemicals against biological
targets using cell-based assays in laboratories. Promising chemicals (\leads") are then tested in animal
disease models. Candidates that survive the animal testing then move on to expensive clinical trials.
As already mentioned, only a small percentage of these candidates survive the ordeal of clinical trials
to become a product, often due to unforeseen side eects, or lack of ecacy in human subjects. Lack of
link between pharmacological activity against targets and clinical eectiveness is the principal culprit
for the later high attrition rate at later clinical stage. The problem lies in the risky practice of using
laboratory screening and animal disease models to predict therapeutic ecacy in human. As it turns
out, the lab screening and animal models often have \inadequate predictive power".26
Capitalizing on herbal medicine knowledge may lead a way out of this costly dilemma. Briey,
botanical extracts can be directly evaluated for clinical ecacy rst rather than subjected to initial
chemical isolation rst. This releases drug discovery from absolute reliance on laboratory screens
and enables the development of drugs for poorly understood diseases that lack laboratory screening
methods and animal models. These products can then be developed either as botanical drugs -
standardized, heterogeneous mixtures - or as puried single-chemical entity drugs.
10A new drug development paradigm, neutraceuticals, championed by Pzer, seeks to accomplish this
end. At an international conference on traditional Chinese medicine, Pzer's representative described
this new paradigm:
\The development paradigm for naturalceuticals diers from the established pharmaceu-
tical strategy in that it seeks up front to rapidly address clinical ecacy with candidates having
anecdotal or folklore histories of use in humans, before investing in costly, time-consuming R&D
work.... Opportunities with proven clinical ecacy may become fully invested for the costly
process..... While this approach appears to turn conventional R&D on its head, it only ac-
knowledges the way drugs were discovered once upon a time."27
Indeed, developing drugs from plants are not new to American pharmaceutical companies. Taxol,
Aspirin, Menthol, Morphine, just to name a few, are examples of single-ingredient drugs derived from
plants. What is new is taking advantage of the traditional knowledge in herbal medicines to give the
drug development process a head start.
11Second, herbal medicines oers a holistic approach to complement a pure reductionism approach
toward diseases, namely, the \silver bullet" approach. The drug industry often prizes itself for its
scientic and reductionism approach toward drug development. But the history shows that many
blockbuster drugs came not necessarily as a result of impeccable R&D, but as a result of lucky breaks.
For example, the initial discovery of Viagra came from a surprising \side eect" in clinical trials
designed for heart conditions.28 The upshot is that merits of the reductionism approach may be
greatly exaggerated to the exclusion of other useful approaches.
In contrast to the \silver bullet" approach, herbal medicines often integrate preventative measures
with curative measures. For example, traditional Chinese medicine recipes typically contain multiple
herbs. While one herb alleviates disease directly, the others may work by promoting general well
being of the body to boost its defense abilities. Such a strategy indeed makes sense in view of the
modern knowledge of how our immune system works. Modern medicine informs us that by boosting
our immune systems, we can help our bodies to ght diseases.
Tied to the holistic approach is the third advantage of herbal medicines, namely, synergism among
dierent components. While the mechanism of most herbal medicines remains elusive, it appears that
synergy among dierent elements can be an important part of their overall medicinal eects. Indeed,
laboratory studies have demonstrated the existence of such synergy at the molecular level for some
traditional Chinese medicine. For example, researchers from University of Maryland reported that an
extract from the roots of a Chinese medicinal herb was found to have antibacterial synergy.29 Such
synergistic action may confer a unique advantage, especially in dealing with complex diseases with
polymorphic nature that are recalcitrant to the conventional single chemical entity drugs. To this end,
many traditional formulas have been reported to exhibit activity against asthma, metabolic diseases,
pain, depression, infectious diseases including AIDS and cancer.30 The claims for treating cancer has
been supported by ndings at National Institute of Health (NIH). Researchers at National Products
Branch at the National Institute of Health (NIH) reported that Camptothecin (CPT) isolated from
extracts prepared from the barks of a Chinese medicinal tree, showed broad-spectrum anti-tumor
activity.31 In fact, Pharmacia Upjohn is producing and marketing a CPT analog, CPT-11, under
the trade name of camptosar or irnnotecan.32 There are additionally over 130 clinical trials involving
dierent versions of CPT analogs, for treating diverse cancers, at early and late stages and in cases
with multiple cancers.33
12Validity of Herbal Medicines: Traditional Chinese Medicine as a Case in Study
13Advocating for botanical drugs based on herbal medicine knowledge necessarily begs the question:
are the underlying herbal medicine claims valid? As herbal medicines encompass a formidable range of
medicines from vastly dierent sources, this section examines only the validity of traditional Chinese
medicine. It is important to stress, however, that the regulatory issues discussed in this paper should
be generally applicable to any herbal medicines that are comparably supported by empirical data as
traditional Chinese medicine.
The prevalence of traditional Chinese medicine in China in this day of age at least suggests its ef-
fectiveness. In China, where western drugs are widely available and relatively aordable in major
cities,34 a recent survey reveals that a majority of consumers view traditional Chinese medicine as
equally or more eective than western drugs.35 The perception is not surprising. Long history of
trial-and-error practice and documentation have accumulated a wealth of empirical knowledge and
clinical data about the eects of herbs on diseases and their associated side eects.
While prevalence at best builds a circumstantial case for the validity of TCM claims, pharmacological
and/or clinical studies performed in the west supply direct evidence.
To this end, a weighty piece of evidence came from a recent controversy involving Merck, a pharma-
ceutical powerhouse, and Pharmanex, a California-based dietary supplement manufacturer. In this
case, Cholestin, a dietary supplement based on traditional Chinese medicine knowledge turns out to
contain the same active ingredient as Mevacor, Merck's FDA-approved prescription drug.36 Red yeast
rice, traditionally prepared by fermenting non-glutinous rice with red yeast, has long been known for
its cholesterol-lowering ability. Indeed, the classical book on TCM, Ben Cao Gang Mu (Compendium
of Materia Medica, 1578 A.D.) describes it as \invigorate spleen, digestion, and promote blood cir-
culation and resolve blood stasis."37 Pharmanex developed a red yeast rice extract and marketed
under the name \Cholestin". It turned out, that Cholestin contains a natural substance, mevinolin,
which is chemically identical to the active ingredient, lovastatin, in the prescription drug, Mevacor.
Coincidentally, Mevacor, was developed and marketed by Merck for the treatment of high cholesterol
and heart disease.38 The story illustrates that ancient empirical-based traditional Chinese medicine
knowledge and costly state-of-the-art western pharmaceutical research can converge.
The validity of traditional Chinese medicine is not limited to this single drama. In fact, laboratory
studies validating traditional Chinese medicine claims are abundant in scientic literature.39 More-
over, clinical trials on products developed based on traditional Chinese medicine knowledge in the
US and in Europe lend further support to its validity.40 In the United States, for example, clinical
trials funded by NIH { some now in Phase III { suggest that ginkgo extract may be eective for
Alzheimer's disease, that chondroitin sulfate may aect osteoarthritis, and that saw-palmetto extract
might ameliorate benign prostrate hypertrophy.41
14The ip Side: What Western Drug Development Process Oers Herbal Medicine
While herbal medicines oer hope for drug development, the argument is equally compelling that
herbal medicines need the injection of rigorous clinical validation and pharmacological studies. On its
own, herbal medicines have slim hope of entering the mainstream of healthcare in the United States.
This is because herbal medicines in their traditional forms suer a myriad of decits. Just to name a
few: the heavy reliance on anecdotal data, the lack of randomized controlled clinical data to substan-
tiate the claims, overly broad and often vague claims, the lack of quality assurance, and an unfounded
panacea \cure all" belief.42 These decits, if not dealt with properly, will continue to undermine the
legitimacy of herbal medicine. Subjecting herbal medicines to standardized manufacturing practice
and well-controlled clinical trials will help overcome these decits. Developing a drug model for herbal
medicines is thus essential in establishing the true value of herbal medicines and their credibility in
the eyes of American consumers.
In sum, it appears that the tradition-based herbal medicines and the science-based western
drug development regime have something to oer each other. The concept of botanical drugs has the
potential to culminate these mutual benets.
It would be simplistic and presumptuous, however, to view botanical drugs as the answer to all
problems. In fact, there are many challenges for developing botanical drugs. For example, technical
issues are abundant for developing herbal extracts with batch-to-batch quality consistency. As the
endeavor is largely unprecedented, there is no ready protocol to follow. Consequently, companies will
need to invent the wheels as they go along, presenting a risky business model from the perspective of
venture capital investors.
15Furthermore, while botanical drugs promise to lower the cost of drug R&D, the cost may still be
prohibitive for most players except the big powerhouses in the eld. Considering that the current
price tag for a new FDA-approved drug is $800 million, an arbitrary 3
4 reduction still leaves the
price tag at a whopping $200 million. To make the matter worse, the initial stage of botanical drug
development necessarily entails experimentation with new protocols and standardization issues, posing
a higher entry cost that might prevent new entrants into the eld.
Taken together, the idea of botanical drugs promises to capture the best of both worlds. But
putting this idea to practice will not be automatic and eortless. There is thus a need for adequate
regulatory climate to spur industry eorts in this direction. The question then becomes, is the
current regulatory structure adequate to accomplish this goal? Are there any industrial eorts in this
direction? What can be done to promote industrial eorts in the United States?
IV.
Current Regulatory Climate and Its Ramications
DSHEA and its Impact
In 1994, in response to immense political pressure, the Congress enacted the Dietary Supplement
Health and Education Act (DSHEA). Under DSHEA, medicinal herbs can be marketed as dietary
supplements without prior FDA approval. The supplements may carry \structure/function" claims {
claims that a product may aect the structure or functioning of the body { but not claims that they
can treat, diagnose, cure or prevent a disease.
16By oering low market entry cost, DSHEA succeeded in making herbal medicines widely available
by oering low market entry cost. But low market entry cost turned out to be a double-edged sword.
By setting a bare minimum regulatory standard, DSHEA failed to remediate the fallacies associated
with herbal medicines enumerated in the last Section. Three reasons underlie the failures of DSHEA
to make safe and high quality herbal medicines available to consumers who need them.
17First, the lack of FDA approval requirement for marketing dietary supplement means no incen-
tive to conduct any substantive research and development on products. In fact, an \anything goes"
mentality pervades this new cottage industry. Manufacturers are largely free to experiment with
traditional herbs. As one commentator noted: Manufacturers often combine traditional herbs \with
other herbs to make new, non-traditional products, use non-traditional but more cost-eective prepa-
ration techniques, promote traditional herbs for non-traditional purposes, and put them in a more
consumer-friendly yet non-traditional form. This experimentation eliminates whatever safeguards and
level of eectiveness traditional use oers."43 On top of it, tremendous price pressure leads to a \race
to the bottom" in terms of qualities of dietary supplements in the market.
As a result, consumers come to associate questionable eectiveness and harmful side eects with di-
etary supplements. In turn, this serves to reinforce the old distrust for traditional herbal medicines,
and undermines consumer condence in herbal medicines. The downturn in the market for dietary
supplement seems to vindicate this concern.
Second, unsupervised herbal use poses health and safety threats. Many people now use traditional
medicine without informing their physicians, falsely believing that herbal medicines, unlike western
synthetic medicines, have no side eects and no harmful interaction with prescription or OTC drugs.
Third, the requirement that dietary supplements are not permitted to make disease claims prevents
the dissemination of potentially useful information. Ironically, as long as they do not claim treating
diseases, manufacturers are allowed to make unsubstantiated claims on their products, fueling further
safety concerns.
18The deleterious eect of DSHEA is further amplied by its disincentivizing eect on companies
who engage in serious research and development eorts to explore the value of traditional medicines.
To illustrate, consider a rm making herbal medicines. To market in the United States, it is faced
with two options. First, it can market them as dietary supplements. Given the de minimis regulation
in this area, this option appears attractive. Second, if the rm wants to get the imprimatur of FDA
on its product, its only option, at least for the time being, is to develop a new single-chemical-entity
drug from herbs and complete the costly drug approval process. To date, FDA has never approved
a single drug in extract form. Given the two options, it makes every business sense to go with the
dietary supplement route. Its entry cost is low, and it promises quick bucks. The drug route pales in
comparison. It requires large up front investment, and the chance for return remains highly uncertain.
The potential return for drugs developed from herbs is directly threatened by dietary supplement free
riders. As mentioned above, notwithstanding the potential cost-cutting benet herbal medicines may
provide, a drug company still needs to invest substantial amount of money to develop a FDA-approved
drug from herbs. As the drug gets the nod from FDA and gets on the market, it may nd itself com-
peting head on with a dietary supplement containing the same active ingredient. Given the low entry
cost of the dietary supplement industry, and the abundance of dietary supplement companies already
in the United States (numbered between 2000 and 3000), this scenario will not be an infrequent event.
Spared of R&D expenses, these free riders will be able to sell their products at a signicant lower
price. Compounded with pressures from managed health care providers to cut drug costs, patients are
more likely to purchase the cheap substitutes, especially given the added lure of a \natural product".
This nightmarish scenario for pharmaceutical companies has recently been mitigated by the Phar-
manex decision. In this case, the 10th Circuit Court recognized that disincentive eect of the DSHEA
for drug development. The Pharmanex decision stands for the proposition that a company will be
barred from marketing a dietary supplement containing a natural substance that is the active ingre-
dient in a previously approved drug product.44 The bar does not reach, however, those companies
that marketed the same natural substance as a dietary supplement prior to approval of the new drug.
Given the long and drawn out FDA drug approval process, \enterprising" businesses have ample op-
portunities to jump on the bandwagon and hitch a free ride anytime prior to a drug's nal approval.
Indeed, as mentioned above, this \window of opportunity" is currently on average 7 to 12 years.
Pharmaceutical companies are especially vulnerable at the New Drug Application (NDA) stage, after
the drug has gone through three phases of clinical trials and remains promising. The NDA stage takes
on average 2 to 3 years,45 presenting a \golden opportunity" for free riders.
To make the matter worse, drug products developed from botanical products are often unable to
obtain a composition patent due to the fact that these products are naturally arising. They have
to settle for use patents, which are much harder to defend and are thus less valuable. As a result,
companies that engage in the risky enterprise of developing drugs from traditional herbs sees its only
prospect as getting whipsawed. Head, the dietary supplement maker wins, tail, the drug company
loses. Chance of recovering the investment is slim.
In short, rather than promoting the mainstreaming of traditional medicines, the advent of dietary
supplements in practice has the opposite eect. The current bifurcation along the line of dietary
supplement and drug runs the danger of foreclosing industrial eorts in US to develop medicinal herbs
into drug products.
19The Danger: American Companies Losing Competitive Advantages in Developing Botanical Drugs?
20Given the unfavorable regulatory climate, it is no surprise that there are only a handful of US
companies in the eld of developing botanical drugs through the conventional IND/NDA route.46
Six US companies claim to be in the business of developing botanical drugs, including Ancile Pharma-
ceuticals, Pharmanex, Phytomedics, Pharmaprint Botanical Pharmaceuticals, Andes Pharmaceuticals
and Phytoceutica. As an indication of lack of serious industrial eorts in this area, all six companies
are small start-up companies. For example, Ancile Pharmaceuticals, based in California, employs 30
professionals.47 Similarly, Phytomedics, Inc., a New Jersey-based company, has a small R&D sta of
20 scientists.48 Among these companies, only Ancile and Phytomedics have progressed into clinical
trial stage. As of April 2001, Ancile has three allowed IND applications led with the FDA. In Decem-
ber 2000, Ancile successfully completed a double blind, placebo-controlled Phase 2 trial for ANPH
101, a drug product intended for sleep disorders.49 Phytoceuticals, a New Haven based company,
cleared its IND application for one of its drug products for modulating chemotherapy in August 2001.
Phase 1 and 2 clinical trials are currently under way.50 Others, like Phytomedics, are still in the
early stage of drug development of lead identication. For Pharmanex and Pharmaprint Botanical
Pharmaceuticals, botanical drug development through the IND/NDA route remains no more than a
grand vision. Instead, the primary business of these two companies is currently dedicated to market-
ing dietary supplements.51
Ostensibly missing from the scene are major pharmaceutical powerhouses, with Pzer as the only
exception. In the absence of major pharmaceutical players, large-scale investment in this area seems
unlikely.
On the other hand, foreign rms are eager for a slice of the US botanical drug market. In fact,
foreign rms have already got a head start in the game. For example, Phytopharm, a British botan-
ical pharmaceutical company, has been in the business of botanical drug development for over 11
years.52 Back in December 1997, Phytopharm cleared its rst IND application with the US FDA for
its botanical product, Zemaphyte.53 Subsequently, Phytopharm initiated clinical studies in 20 centers
in the US on using Zemaphyte to treat severe ectopic eczema.54 In addition, in September 2000,
Phytopharm announced that it has initiated Phase I clinical evaluation for another botanical product,
P58.55 According to the company news release, \P58 is one of a family of phytochemicals isolated
from traditional treatments for the elderly that have previously been shown to oer signicant benet
in the treatment of senile dementia".56
21Similarly, another British pharmaceutical company, Oxford Natural Products, is dedicated to the
\development of novel pharmaceuticals and nutraceuticals from plants".57 As of 2001, the company
has three products entering clinical evaluations.58 Among them, ONP-17, which treats hepatitis-C
symptoms, is composed of extracts of traditional Chinese and Western herbs. Chronic hepatitis-C
inicts over 300 million patients worldwide. Not shy about its intention to enter the US market,
Oxford Natural Products explicitly points out on its website that in America, hepatitis-C is four
times more prevalent than AIDS.59
22The threat of competition for the US botanical drug market comes not only from European na-
tions. CV Technologies, Inc. (CVT), a Canadian herbal drug developer, has already been engaged
in the business of developing nutraceuticals for over 10 years.60 In October 1999, CVT obtained its
rst IND clearance with the US FDA for its nutraceutical product, CVT-E002.61 CVT-E002 is a
multicomponent extracts from North American ginseng intended for use as a preventative against
acute respiratory infection.62 In September 2000, CVT announced the successful completion of its
rst Phase II clinical trial of CVT-E002, and is ready to proceed with a second, much larger Phase II
clinical trial.63 All these trials are open-labeled, double blind and placebo-controlled.
An unusual dominance of foreign entities among commentators on the US FDA's new Draft Guid-
ance gives another glimpse of the eagerness of foreign rms for the American botanical drug market.
Among 18 who led comments to date, only four are American drug companies, nine are foreign
industrial entities, representing either individual companies or association of companies (see Table
1). According to Dr.Yuan-yuan Chiu, Director of Oce of New Chemistry for Drug Evaluation and
Research at FDA, the disparity in responses possibly indicates a disparity between the United States
and other nations in the level of activities in the eld.64
Table 1. Distribution of commentators on the Draft Guidance
Origination Drug Companies Others (consulting, governmental
agency, trade association)
United
States
4 3
Europe 4 0
Asia 2 1
Canada 3 0
Global 1 (Pzer) 0
Total 14 4
23The lack of industrial eorts in the United States, if left unchanged, can potentially cost America its
competitive advantage in the global market. The American drug industry is not the only one suering
from the current regulatory regime. As pharmaceutical companies shy away from making eective
drugs from herbal medicines, consumers will be deprived of these potentially eective medicines. The
massive under regulation of dietary supplements hardly relieves this deprivation, as the market is now
ooded with dietary supplements with dubious qualities. This unsatisfactory state of aair calls for
changes in regulatory policy.
The Case for Lowering Approval Standards for Botanical Drugs
It is time for FDA to get involved. Americans have grown to trust FDA as the gatekeeper of new
drugs. A stamp of approval of herbal medicines from FDA will pave the way for herbal medicines to
be accepted by the American mainstream.
24A viable alternative is for FDA to alter the current all-or-nothing state of aair: on the one hand
the stringent armed-to-the-teeth regulation for new drugs approval, and on the other, no FDA scrutiny
for marketing dietary supplements. A balance can be struck somewhere in the middle. FDA could
create a new category for botanical drugs, by placing herbal medicines into the FDA approval process
but with substantially lower approval standards.
Adopting standards substantially lower than that required for conventional drugs is justied by the
fact that many herbal medicines already have extensive prior marketing experience before ling appli-
cations with FDA. Take traditional Chinese medicine as an example, four thousand years of trial-and-
error medical practice and documentation have reasonably established their safety and eectiveness.
Their continuing marketing in China and in other Asian, European nations provide further evidence
for their safety.
In fact, many other industrial nations have already adopted similar practice. For example, France
permitted the registration of \vegetable drugs" under \an abridged dossier" in 1990. The safety of
herbal remedies, \historical proof of their widespread traditional use and their well established use
in self-medication" were taken into account.65 Likewise, in Germany, \bibliographic data on the well
established use of herbal medicines are accepted" by the Federal Institute for Drugs and Medical
Devices (the German equivalent of the FDA) for determining safety and ecacy of drug products.66
Some might think that the FDA drug approval standard should not be tempered with to accommodate
a new category of drugs. To the contrary, the conventional drug approval standard for NCE drugs
is not set in stone. In fact, FDA has frequently invoked criticism for its stringent approval standard
and several reforms have been proposed.67 Critic called the approval standard overly stringent and
unnecessary, that it has \become more stringent than is socially optimal".68 Studies have found that
more stringent drug regulations, spurred by the thalidomide tragedy, have increased the drug devel-
opment costs by about 6 percent per year in the United States. Consequently, it has cut by half the
number of new drugs introduced in the United States relative to other industrialized nations.69 The
FDA is blamed for maintaining a higher than optimal drug approval standard out of fear of political
pressures. Approving a nonbenecial and harmful drug leads to more political backlash for FDA than
failing or simply delaying to approve a benecial drug. As put by one critic, \no ocial wants to be
known as the one who approved another thalidomide".70 The result is a net social loss due to failure
to approve a truly benecial drug. Indeed, the cost in increased mortality and morbidity was valued
at $330 million in a 1973 study.71
While no one is holding breath for any quick turnaround by FDA in its conventional drug approval
standard, adopting a lower standard for a new category of drugs requires less administrative over-haul
and is perhaps more likely to succeed.
Some may raise health and safety concerns as a result of reduced FDA scrutiny. While the concern is
legit, the reality is the advent of dietary supplements have already brought threat to public health and
safety. In fact, having FDA involving in standard setting will make botanical drugs safer than their
dietary supplement cousins. As physicians will be involved through the prescription process, they
will be the \learned intermediary" to inform and educate patients. In addition, in contrast to the
scarce information provided on the garden variety of dietary supplements, botanical drugs, like other
prescription drugs, will come with Patient Package Inserts that will supply extensive information.
A second and related concern is that granting the FDA approval to botanical drugs under a reduced
standard may undermine the credibility of FDA and consequently all FDA-approved drugs. This
paranoia is premised on an unfounded assumption that botanical drugs will cause more health and
safety problems than conventional single entity drugs. As mentioned above, extensive clinical data
from millenium of practice and foreign marketing experience indicates that botanical drugs will at
least be as safe, if not safer than the synthetic single-chemical-entity drugs.
Therefore, while there are potential pitfalls, the benets of permitting new botanical drugs outweighs
these pitfalls.
In embracing herbal remedies, FDA will not be stepping out of its usual conservative character and
take on a revolutionary role. Rather, it will be keeping in pace with a movement that has already been
embraced by many dierent sectors of the American society. The following tale of changing names
highlights a gradual acceptance of the unconventional. In the 1950s: the American Cancer Society
had a committee on Quackery. Later, that name is replaced by \questionable methods", followed by
\unproven methods of cancer management". Toady the same committee is named \Committee on
Complementary and Alternative Medicine (CAM)".72 This image of keeping up, rather than starting
a revolution, ts more comfortably with the conservative temperament of the FDA. On the other
hand, inaction will make FDA appear unreasonably stubborn to a sea of change happening in the
larger society and worldwide, and will undermine its credibility in the eyes of consumers.
In summary, giving herbal medicines green lights under a new standard that takes into account the
clinical and prior market experience is optimal for the social and economic benets. United States
is already late to the game of herbal medicines. For American pharmaceutical companies to stay
competitive in the global economy, a fostering regulatory environment is urgently needed.
25V.
FDA Draft Guidance
The FDA Draft Guidance for Industry on Botanical Drug Products, released in August 2000 for
public comments, signals a meaningful rst step toward a favorable regulatory climate for companies
to engage in substantial R&D eorts with herbal medicines.73 In this document, FDA, for the rst
time in its history, proposes to approve botanical drugs in extract forms as a new class of drugs.
The Draft Guidance is signicant for two reasons. First, it has the potential, if enforced appropriately,
to eliminate non-conforming standards and bring about more uniformity in the use of herbal medicine,
which is now largely dominated by the chaos of dietary supplements. It will promote safety, quality
and ecacy of herbal medicine usage. Second, with the blessing of FDA, herbal medicines, in their
reincarnation as botanical drugs, will nally have a real hope of entering the mainstream of healthcare
in the United States.
To briey summarize, the Draft Guidance explains when a botanical drug may be marketed under
an over-the-counter (OTC) drug monograph, and when FDA approval of a new drug application
is required for marketing. It also provides guidance to sponsors on submitting investigational new
drug applications (INDs) for botanical drug products. Recognizing the complexity of botanicals
and prior marketing experience with many herbal medicines, the Draft Guidance deems appropriate
to enact regulatory policies that dier from those for synthetic, semisynthetic, or otherwise highly
puried drugs. In particular, in certain circumstances, prior domestic marketing data is proposed to
substitute, either partially or completely, the preclinical data to support an IND for initial clinical
studies.
This section will focus on the coverage of the Draft Guidance and new approval standard for botanical
drugs. The analysis will take into account relevant public comments submitted to FDA to date.
26Scope of Botanical Drugs
The Draft Guidance delineates the scope of botanical drugs quite narrowly. The basic denition
of botanical drugs in the Draft Guidance keeps in line with the basic approach of the Food Drug &
Cosmetics Act (FDCA), which is to distinguish between food and drug on the basis of intended use.
Thus the Draft Guidance denes botanical drugs as \a botanical product that is intended for use as a
drug; a drug product that is prepared from a botanical drug substance".74 From this basic denition,
the Draft Guidance explicitly excludes \highly puried or chemically modied substances derived from
botanical sources" from the reach of botanical drugs.75 As a justication for this exclusion, the Draft
Guidance explained that once puried, these substances \can readily be fully characterized".76
On a rst blush, the narrow denition appears to indicate FDA's reluctance to fully embrace herbal
medicines, as it stops short of encouraging full-edged conventional drug development building on
herbal medicine knowledge. But there may be other justications for this approach. For example,
the narrow denition may well indicate that FDA has accepted the conventional wisdom of herbal
medicine practitioners, that \the whole is greater than the parts". Under the idea of synergism,
that multiple components in many herbal extracts work together to alleviate diseases, developing a
single-chemical-entity drug from herbal medicine appears not to be advantageous, not to mention the
potential side eects resulting from the puried chemicals.
27Furthermore, FDA may need to retain a uniform approval standard for new-chemical-entity (NCE)
drugs. FDA would not want to discriminate among NCE drugs developed with dierent methodologies,
for example, recombinant biotech drugs, drugs developed using genomic knowledge, versus drugs
developed from herbal medicines. Given the current technology complexity in drug development,
choosing methodologies is beyond the expertise of a federal bureaucracy like FDA. Thus, it is perhaps
wise for FDA not to play favoritism for NCE drugs.
28It is interesting to note that some industrial nations have adopted broader conceptions of botanical
drugs. For example, in France, herbal medicines are simply dened as medicines that have exclusively
plants or plant extracts as active ingredients.77 Similarly, in Greece, a regulation for herbal medicines,
published in 1994 by the Ministry of Health, dened herbal medicines as medicines that contain as
active ingredients only plants or preparations of plants.78 These broader denitions would cover NCE
drugs developed from plants. It should be noted, however, that regulations for NCE drugs in these
nations are much less stringent than those in the United States. Thus, granting herbal medicine status
to NCE drugs derived from botanicals does not amount to a big compromise in the approval standards
in France and Greece. To put it another way, the narrow conception of botanical drugs in the Draft
Guidance could simply be a function of the highly stringent regulation for conventional drugs imposed
by the FDA in the United States. Absent a drastic reform to lower the NCE drug approval standard,
bringing in NCE drugs developed from botanicals under the botanical drugs may be too drastic a
measure for the FDA.
Makers of new NCE drugs derived from medicinal herbs are thus directly barred from beneting under
the relaxed approval standard. It is unclear, however, what comes within the ambit of \highly puried"
and therefore gets excluded from the scope of botanical drugs. The denition section gives no denition
to the term \highly puried".79 As pointed out by the comment from Tibotec Pharmaceuticals Ltd.,
a Belgium-based pharmaceutical company, the preparation of many herbal extracts entails multiple
steps of purication.80 Would the herbal extracts prepared this way satisfy the \highly puried"
standard in the Draft Guidance and thus not a botanical drug for the purpose of the Guidance? Such
a construction is unlikely as it directly conicts with the basic premise of the Draft Guidance, which
is to grant new drug status to botanical extracts. The nal Guidance should clarify that the term
\highly puried" is limited to drugs with single active chemical ingredient puried from botanicals.
Regulatory Carrots: Games of Gives and Takes
The Draft Guidance highlights three main benets for botanical drug developers. In general, the NDA
route for botanical drugs espoused by the Draft Guidance parallels closely the route for a NCE drug.
29The foremost benet is the recognition of prior human use as supporting data in the initial stages
of clinical trials. For botanical products legally marketed in the United States with no known safety is-
sues, the Chemistry, Manufacturing and Control (CMC) and animal toxicology data may be \markedly
reduced" for initial clinical studies.81 Indeed, the Draft Guidance points out that \in most cases, ad-
ditional toxicology and CMC data will not be required".82 But not all prior human use data are
treated equally. Botanical products that have been previously marketed only in foreign markets need
to supply more information to initiate clinical phase I and II. Decisions as to the nature of information
needed for these products will be determined on a case-by-case basis.83 At the other extreme of the
spectrum, those botanical products that have not been legally marketed anywhere or have known
safety issues are subject to the same standard as their NCE counterparts.
30This benet, however, stops at Phase III. Here the Draft Guidance turns a sudden blind eye to the
fact that high quality human safety data is available for many botanical products. Botanical drugs are
held to the same high standard as a NCE drug for the purpose of Phase III clinical. Manufacturers
will have to supply the whole gamut of full non-clinical toxicology program, full clinical program and
equivalent CMC data. As one commentator pointed out, the reservation here highlights the general
diculty to alter \institutional thinking" at FDA.84 The reservation here gives the Draft Guidance a
schizophrenic character and seriously undermines the benets granted to botanical drugs. The next
section will discuss more about its eect on incentives for botanical drug makers.
Second, the Draft Guidance indicates that applicants for a botanical drug may not need to identify
its active constituents during the IND stage or in an NDA submission if identication \is shown to
be infeasible".85 More importantly, the Draft Guidance acknowledges broadly that in many cases of
botanical drugs, neither the active ingredient nor its biological activity is well characterized.86 This
acknowledgement is likely to gure into the case-by-case approval review process and tip the scale
further to favor approving botanical drugs under a reduced standard.
The problem with this regulatory carrot, however, is that it is tethered to an ambiguous \infeasible"
standard. Several comments raised this objection. Consumer Healthcare products Association sug-
gested that FDA not to \leave open-ended statements" that can lead to inconsistent interpretations.87
Phytopharm, a UK-based pharmaceutical company requested that the nal guidance clarify the issue
by including examples of botanical drugs that satisfy the burden of demonstrating infeasiblity.88
Thirdly, a less articulated but nonetheless valuable benet is the exemption from the combination
drug regulations.89 By denition, botanical drugs are combinations of multiple components, and
sometimes, multiple active ingredients. Under the combination drug regulations, the maker of a xed-
combination drug would have to demonstrate that each component or active ingredient contributes to
the claimed therapeutic eects. Imposing such a requirement on botanical drugs would mean practical
death for these drugs. Thus, an exemption from the requirement is valuable. 31The exemption is limited, however, to botanical drug products that are derived from a single part
of a plant, say leaves, stems, roots or seeds, or from an alga or macroscopic fungus.90 Botanical
drug products that are composed of multiple parts of a single plant, or of parts from dierent plants,
are not within the exemption. Thus, these drugs will still have to comply with the combination
drug requirement. FDA, however, does not completely shut the door. A ray of hope remains as FDA
indicated its intention to exempt this group of botanical drugs from the combination drug requirement
\under certain circumstances".91
The exemption from combination drug requirement is consistent with the general recognition of the
diculty of identifying active ingredients in the herbs. In addition, the exemption is also in line with a
more fundamental recognition that herbal medicines work in ways dierent from that of conventional
NCE drugs. Synergism among multiple components, as mentioned above, underscores the need for
crafting rules dierent from conventional NCE drugs.
Potential Ramication for Makers of Botanical DrugsOn the Cost Side
32Despite its best of intention, the Draft Guidance delivers, at best, limited incentives for the devel-
opment of botanical drugs. Lowering the barrier to initial phases of clinical trials for botanical drugs
conceivably reduces the cost of preparing botanical drug candidates for clinical trials. But the hurdle
of the Phase III clinical remains formidable. As Phase III entails the most extensive clinical trials and
thus most expenses, preserving the stringent standard for Phase III clinical means that the bulk of
the cost in bringing a drug to market will not go away for botanical drugs.
Furthermore, retaining the same requirement for Phase III may impose more costs on botanical drug
makers than on NCE drug makers. As FDA itself concedes in the Draft Guidance, the nature of
botanical products makes them non-conducive to conventional methods of purication and character-
ization. In fact, to justify its exclusion of \highly puried" substances from the scope of botanical
drugs, FDA oers the reason that \because these substances can readily be fully characterized".92
A negative corollary of that statement is that botanical drug products are much harder to be \fully
characterized" according to FDA's standard. Yet FDA presses on and demands essentially the same
stringent requirement for botanical drugs as for NCE drugs. For prospective botanical drug devel-
opers, a requirement to comply with the arcane standards of Phase III, originally designed for NCE
drugs, may translate into more costs. Thus, by essentially forcing square pegs into round holes, FDA
places additional burden on botanical drug developers. In a sense, FDA is giving benets to botanical
drug makers with one hand (concession at Phase I and II), and taking back with another (reservation
at Phase III). The net result is de minimis benet for botanical drug makers.
To further complicate the picture, the Draft Guidance provides no simple \cook book" for botanical
drug applications.93 While the document signals a clear willingness by FDA to work with drug makers
to foster the growth of botanical drug development, the guidance itself is unfortunately perforated
with ambiguities. The use of \may" and \might", instead of \shall" and \must" is profuse throughout
the document. Similarly, as mentioned above, the use of phrases such as \shown to be infeasible" and
\under certain circumstances" leaves many approval standards undesirably open-ended.
To an industry that certainty equals gold, uncertainty undercuts incentives. As expected, comments
from pharmaceutical industry vigorously objected the ambiguities in the document. They uniformly
requested FDA to provide clarication in the nal guidance. Conceivably, industry will need to rely
on the framework provided by the nal guidance to shape itself.
This said, it should be recognized that the profuse use of ambiguous language could simply be an
indicia of a new eld. At the beginning stage of opening up any new eld, exible standards, rather
than rigid rules, are more workable and conducive to later and gradual improvement. Given this
consideration, the nal Guidance is perhaps unlikely to incorporate much clearer standard.
In this context, it is worth noting that historically, IND and NDA reviews have been conducted on a
case-by-case basis for NCE drugs94. By the same token, IND and NDA reviews for botanical drugs
will likely be subjected to the same case-by-case review. Thus, the implication for the industry will
become increasingly clear as FDA begins to approve botanical drugs. Currently there are more than a
hundred botanicals either individually or in formulas currently going through FDA's clinical trials.95
To date, no single NDA has been granted to a botanical drug product yet. How FDA carries out the
Guidance in the IND/NDA approval process for these botanical drugs in the next few years will be
instrumental in shaping the direction of the industry.
33On the Return Side
34The incentive structure for botanical drugs, provided by the Draft Guidance, tracks the structure
for other kinds of drugs. In other words, the Draft Guidance provides that botanical drugs enjoy
5-year marketing exclusivity if it is a new chemical entity, or otherwise a 3-year exclusivity from the
time of approval. The dierential treatment depends on whether a drug's active constituent is a new
chemical entity.
This simple scheme turns out not to be so simple with botanical drugs. As acknowledged in the Draft
Guidance, in most cases, the active constituent of a botanical drug will be unknown.96 Therefore the
length of the marketing exclusivity for these botanical drugs depends on how one interprets the term
\active constitute" in the Draft Guidance. A narrow construction leads to the conclusion that most
botanical drugs with unknown active constituents will enjoy only 3-year marketing exclusivity. On the
other hand, a broader construction, as espoused by the Consumer Healthcare Products Association,
suggests that the entire botanical drug product should be considered the active constituent, and thus
the \new chemical entity".97 Under this broad construction, these botanical drugs will enjoy 5-year
marketing exclusivity.
Moreover, the Draft Guidance does nothing to prevent the free rider problem mentioned in Section
IV. The marketing exclusivity only works against other drug makers, not against dietary supplements
manufacturers. Therefore this arrangement does not solve the remaining free rider problem after the
limit prescribed by the Pharmanex decision, as described in Section IV. More specically, dietary
supplement manufacturers are free to market a dietary supplement with the same or substantially
similar herbal extracts as that in a botanical drug, as long as they can prove that they marketed their
product prior to the FDA approval of the botanical drug. The advent of nal guidance means that
botanical drugs will have the blessing of FDA approval and come with better quality and safety as-
surance. But they will also come at a substantially higher price compared to their dietary supplement
counterparts, making botanical drug makers vulnerable to price undercutting by dietary supplement
manufacturers. This free rider problem threatens the chance for pharmaceutical companies to recoup
their R&D costs, which will be substantial under the Draft Guidance.
Taken together, the Draft Guidance fails to deliver real and substantial cost-cutting benet for botan-
ical drug developers. At the same time, it leaves the return for botanical drugs uncertain.
35A Viable Solution for the Industry?
To counter the free rider problem, pharmaceutical companies could take on the oense. The idea
is simple. Pharmaceutical companies can disarm potential free riders by taking over their weapon:
the market for dietary supplements. Before initiating clinical trials on any botanical drug candidates,
or during clinical trials, pharmaceutical companies could market herbal extracts containing the same
ingredients as dietary supplements themselves at the same time they pursue R&D for botanical drug.
Considering the low entry cost for the dietary supplement market, big pharmaceutical companies can
easily establish itself in this market. Bayer is a successful example in this regard.98 In addition, big
pharmaceutical companies may capitalize on their name powers and eectively drive out small dietary
supplement manufacturers and block any future competitors marketing the same herbal extracts.
Although no big pharmaceutical companies have taken this route to date, small pharmaceutical com-
panies have seen this strategy as a viable business model and have put it to practice. For example,
CV Technologies (CVT), a small Canadian pharmaceutical company, has marketed COLD-FX as a
dietary supplement for cold prevention for some time. At the same time, it is actively conducting
Phase I and II clinical trials for the same product under the name CVT-E002.99 Upon its successful
completion of Phase II clinical trials, CVT will seek a major pharmaceutical partner to license CVT-
E002 for Phase III testing, drug approval by FDA and marketing of the new drug. The fact that CVT
already has the dietary supplement market for the drug product is certainly a favorable consideration
in the negotiation process. This strategy is also what Pharmanex, a California-based pharmaceutical
company, proposes to do.100
36Proposals for Further Rule Changes
While the Draft Guidance is a meaningful step forward, it still imposes daunting hurdles for botanical
drug makers to overcome. To eectively promote the growth of botanical drug development and to
bring benecial drugs at faster rate to patients, the nal guidance should consider making the following
changes.
The foremost change is due in the requirement for the Phase III clinical trials. Prior human use data
should be taken into account as valid data in this phase, consistent with the approach taken in the
Draft Guidance for the rst two phases. In addition, FDA should consider the nature of the botanical
products when crafting standards for Phase III. Blind adherence to the existing standards designed
for NCE drugs makes no analytical sense. To aid its eorts to craft standards that are applicable
to botanical products, FDA may capitalize on the resource and expertise of another federal agency,
namely the newly created National Center for Complementary and Alternative Medicine (NCCAM).
The nal guidance should also state clearly that all the special benets available to small Molecular
Weight or Recombinant drug products are oered to botanical drug products. For example, if a
botanical drug is intended for use for a life-threatening disease, all the provisions for expedited review,
treatment INDs, emergency INDs, should apply to the botanical drug. Similarly, if a botanical drug is
intended for use for a rare disease, it should also be considered under the Orphan Product Amendments
(including Orphan Product Designation, tax advantages, and 7-year marketing exclusivity).101
37